Dr. Basu is a Research Assistant Professor with the Division of Experimental Pathology.
Dr. Basu is a molecular cell biologist specializing in signal transduction pathways that govern cell division and cancer. His research currently explores how Growth Factor-Oncogene interactions contribute to molecular oncogenesis, particularly in cancers arising during embryonic development. He is interested in the molecular and cellular factors that fuel tumor growth, progression, and malignant transformation in NRAS and BRAF-driven diseases. His research aims to identify novel therapeutic targets to prevent the development of cancer from benign pre-cancerous lesions.
NIH grant R03CA280130 in the year 2023 to study the molecular oncogenesis of congenital Neurocutaneous melanocytosis in a preclinical transgenic mouse model.
View Dr. Basu's publications on PubMed
Basu D. Therapeutic Strategies in Neurocutaneous Melanocytosis. Anticancer Res. 2024 Dec;44(12):5157-5167. doi: 10.21873/anticanres.17341. PMID: 39626934.
Basu D, Salgado CM, Bauer B, Hoehl RM, Moscinski CN, Schmitt L, Reyes-Múgica M. Histone deacetylase inhibitor Vorinostat (SAHA) suppresses micropthalmia transcription factor expression and induces cell death in nevocytes from large/giant congenital melanocytic nevi. Melanoma Res. 2021 Aug 1;31(4):319-327. doi: 10.1097/CMR.0000000000000749. PMID: 34054057.
Basu D, Salgado CM, Patel JR, Zabec J, Hoehl RM, Bauer B, Reyes-Múgica M. Pluripotency markers are differentially induced by IGF1 and bFGF in cells from patients' lesions of large/giant congenital melanocytic nevi. Biomark Res. 2019 Jan 14;7:2. doi: 10.1186/s40364-018-0152-9. PMID: 30675361; PMCID: PMC6332894.
Basu D, Salgado CM, Bauer B, Khakoo Y, Patel JR, Hoehl RM, Bertolini DM, Zabec J, Brzozowski MR, Reyes-Múgica M. The Dual PI3K/mToR Inhibitor Omipalisib/GSK2126458 Inhibits Clonogenic Growth in Oncogenically-transformed Cells from Neurocutaneous Melanocytosis. Cancer Genomics Proteomics. 2018 Jul-Aug;15(4):239-248. doi: 10.21873/cgp.20082. PMID: 29976629; PMCID: PMC6070711.
Patel J, Salgado CM, Múgica MR, Basu D. Insulin-like growth factor 1 receptor signaling via Akt: a general therapeutic target in neurocutaneous melanocytosis? Neuro Oncol. 2016 Jan;18(1):142-3. doi: 10.1093/neuonc/nov271. PMID: 26667139; PMCID: PMC4677422.